Drug Development’s New Model: Biosimulation from Discovery to Label Expansion
Key Highlights: How predictive technologies reshape drug development, mitigating project risks, navigating novel biomarkers, predicting…
Danielle Pillsbury2024 年 2 月 2 日
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. （纳斯达克股票代码：CERT), a global leader…
Danielle Pillsbury2024 年 2 月 1 日
Navigating Market Access for Healthcare Products: The Power of the Global Value Dossier
This blog defines the global value dossiers and explains how BaseCase can support creating interactive…
Certara2024 年 1 月 24 日
Navigating the “Patent Cliff”: Omni-channel Strategies for Loss of Exclusivity and Established Products
Join us to understand the dynamics of the pharmaceutical market and learn how to maintain…
Danielle Pillsbury2024 年 1 月 24 日
Understanding the Role of Your Discovery Asset’s Target Product Profile
If you work at a biotechnology start-up, you’re probably excited about your compound assets, particularly…
Certara2024 年 1 月 19 日
Streamlining Your NCA Workflow
准备递交的 PK 分析面临着许多数据和合规方面的挑战。To work efficiently,…
Danielle Pillsbury2024 年 1 月 18 日
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
To assess real-world treatment patterns in patients diagnosed with hormone receptor positive (HR+), human epidermal…
Jim Gallagher2024 年 1 月 17 日
Higher Standards: Achieving Cleaner Data, Faster, from Protocol to Submission
Join our webinar to explore best practices for harnessing the power of standards, without a…
Danielle Pillsbury2024 年 1 月 16 日
Real-world application of PBPK in drug discovery
The utility of PBPK models in support of drug development has been well documented. During…
Jim Gallagher2024 年 1 月 11 日
